Spots Global Cancer Trial Database for p53 dysfunction
Every month we try and update this database with for p53 dysfunction cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | NCT02203513 | Ovarian Cancer Breast Cancer Prostate Cancer | LY2606368 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | NCT02203513 | Ovarian Cancer Breast Cancer Prostate Cancer | LY2606368 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction | NCT03734198 | Relapsed or Ref... | Ibrutinib Daratumumab | 18 Years - | French Innovative Leukemia Organisation | |
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction | NCT03734198 | Relapsed or Ref... | Ibrutinib Daratumumab | 18 Years - | French Innovative Leukemia Organisation |